Last reviewed · How we verify
Daclizumab or Basiliximab
Daclizumab and Basiliximab are monoclonal antibodies that block the IL-2 receptor (CD25) on T cells, preventing T cell activation and proliferation.
Daclizumab and Basiliximab are monoclonal antibodies that block the IL-2 receptor (CD25) on T cells, preventing T cell activation and proliferation. Used for Prevention of acute organ rejection in renal transplantation (Basiliximab approved), Multiple sclerosis (Daclizumab in development/phase 3), Autoimmune hepatitis and other autoimmune conditions (investigational).
At a glance
| Generic name | Daclizumab or Basiliximab |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | IL-2 receptor antagonist (monoclonal antibody) |
| Target | CD25 (IL-2 receptor alpha subunit) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Both drugs bind to CD25, the alpha subunit of the high-affinity IL-2 receptor expressed on activated T lymphocytes. By blocking IL-2 signaling, they suppress T cell-mediated immune responses. Daclizumab is a humanized antibody while Basiliximab is a chimeric antibody; both are used as immunosuppressants in transplantation and autoimmune conditions.
Approved indications
- Prevention of acute organ rejection in renal transplantation (Basiliximab approved)
- Multiple sclerosis (Daclizumab in development/phase 3)
- Autoimmune hepatitis and other autoimmune conditions (investigational)
Common side effects
- Infection (bacterial, viral, fungal)
- Lymphopenia
- Headache
- Gastrointestinal disturbances
- Hypersensitivity reactions
Key clinical trials
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (PHASE2)
- Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (PHASE3)
- Efficacy of Islet After Kidney Transplantation (PHASE3)
- Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists (NA)
- A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD (PHASE2)
- Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: